Jin Yang Pharmaceutical Co., Ltd.

KOSDAQ:A007370 Stock Report

Market Cap: ₩66.8b

Jin Yang Pharmaceutical Balance Sheet Health

Financial Health criteria checks 2/6

Jin Yang Pharmaceutical has a total shareholder equity of ₩118.0B and total debt of ₩85.6B, which brings its debt-to-equity ratio to 72.5%. Its total assets and total liabilities are ₩227.6B and ₩109.6B respectively. Jin Yang Pharmaceutical's EBIT is ₩7.6B making its interest coverage ratio 5.7. It has cash and short-term investments of ₩4.2B.

Key information

72.5%

Debt to equity ratio

₩85.58b

Debt

Interest coverage ratio5.7x
Cash₩4.16b
Equity₩118.02b
Total liabilities₩109.58b
Total assets₩227.60b

Recent financial health updates

Recent updates

Shareholders Shouldn’t Be Too Comfortable With Jin Yang Pharmaceutical's (KOSDAQ:007370) Strong Earnings

Nov 22
Shareholders Shouldn’t Be Too Comfortable With Jin Yang Pharmaceutical's (KOSDAQ:007370) Strong Earnings

Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370) Shares Fly 32% But Investors Aren't Buying For Growth

Aug 19
Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370) Shares Fly 32% But Investors Aren't Buying For Growth

These 4 Measures Indicate That Jin Yang Pharmaceutical (KOSDAQ:007370) Is Using Debt Reasonably Well

Aug 12
These 4 Measures Indicate That Jin Yang Pharmaceutical (KOSDAQ:007370) Is Using Debt Reasonably Well

Jin Yang Pharmaceutical's (KOSDAQ:007370) Problems Go Beyond Weak Profit

May 23
Jin Yang Pharmaceutical's (KOSDAQ:007370) Problems Go Beyond Weak Profit

A Look At The Intrinsic Value Of Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370)

Mar 22
A Look At The Intrinsic Value Of Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370)

Here's Why I Think Jin Yang Pharmaceutical (KOSDAQ:007370) Is An Interesting Stock

Mar 04
Here's Why I Think Jin Yang Pharmaceutical (KOSDAQ:007370) Is An Interesting Stock

These 4 Measures Indicate That Jin Yang Pharmaceutical (KOSDAQ:007370) Is Using Debt Safely

Feb 11
These 4 Measures Indicate That Jin Yang Pharmaceutical (KOSDAQ:007370) Is Using Debt Safely

Are Jin Yang Pharmaceutical Co., Ltd.'s (KOSDAQ:007370) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

Jan 21
Are Jin Yang Pharmaceutical Co., Ltd.'s (KOSDAQ:007370) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

Does Jin Yang Pharmaceutical's (KOSDAQ:007370) Share Price Gain of 49% Match Its Business Performance?

Jan 04
Does Jin Yang Pharmaceutical's (KOSDAQ:007370) Share Price Gain of 49% Match Its Business Performance?

We're Not So Sure You Should Rely on Jin Yang Pharmaceutical's (KOSDAQ:007370) Statutory Earnings

Dec 17
We're Not So Sure You Should Rely on Jin Yang Pharmaceutical's (KOSDAQ:007370) Statutory Earnings

Here's Why We Think Jin Yang Pharmaceutical (KOSDAQ:007370) Is Well Worth Watching

Nov 30
Here's Why We Think Jin Yang Pharmaceutical (KOSDAQ:007370) Is Well Worth Watching

Financial Position Analysis

Short Term Liabilities: A007370's short term assets (₩43.7B) exceed its short term liabilities (₩20.7B).

Long Term Liabilities: A007370's short term assets (₩43.7B) do not cover its long term liabilities (₩88.9B).


Debt to Equity History and Analysis

Debt Level: A007370's net debt to equity ratio (69%) is considered high.

Reducing Debt: A007370's debt to equity ratio has increased from 21.1% to 72.5% over the past 5 years.

Debt Coverage: A007370's debt is not well covered by operating cash flow (18.3%).

Interest Coverage: A007370's interest payments on its debt are well covered by EBIT (5.7x coverage).


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 07:42
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jin Yang Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution